Loading…
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-26M | $-26M | $-12M | 154.2% | - | 91.4% |
| 2024 | $0M | $-13M | $-14M | $-12M | 88.7% | - | -77.3% |
| 2023 | $0M | $-59M | $-60M | $-8M | 64.0% | - | -1471.9% |
| 2022 | $0M | $4M | $4M | $-0M | 1.3% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Operating Expense | - | 0.95 | 8.84 | 53.56 | 26.14 |
| Research And Development | - | 5.77 | 4.40 | 31.03 | 11.11 |
| Selling General And Administration | - | 0.95 | 4.44 | 22.53 | 15.03 |
| Total Expenses | - | 0.95 | 8.84 | 53.56 | 26.14 |
| Operating Income | - | -0.95 | -8.84 | -53.56 | -26.14 |
| Total Operating Income As Reported | - | -13.72 | -8.84 | -53.56 | -26.14 |
| EBITDA | - | 4.41 | -58.89 | -13.14 | -25.57 |
| Normalized EBITDA | - | -0.95 | -58.89 | -4.69 | -25.63 |
| EBIT | - | 4.41 | -59.27 | -13.54 | -26.08 |
| Interest Expense | - | 0 | 1.21 | 0.18 | 0.20 |
| Net Interest Income | - | 0 | -1.21 | -0.18 | -0.20 |
| Other Non Operating Income Expenses | -10.38 | -7.38 | -50.43 | 48.47 | - |
| Other Income Expense | - | 5.36 | -50.43 | 40.02 | 0.06 |
| Interest Expense Non Operating | - | 0 | 1.21 | 0.18 | 0.20 |
| Net Non Operating Interest Income Expense | - | 0 | -1.21 | -0.18 | -0.20 |
| Pretax Income | - | 4.41 | -60.48 | -13.73 | -26.28 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 1.13 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | 4.41 | -60.48 | -13.73 | -26.28 |
| Net Income From Continuing And Discontinued Operation | - | 4.41 | -60.48 | -13.73 | -26.28 |
| Net Income From Continuing Operation Net Minority Interest | - | 4.41 | -60.48 | -13.73 | -26.28 |
| Net Income | - | 4.41 | -60.48 | -13.73 | -26.28 |
| Net Income Common Stockholders | - | 4.41 | -60.48 | -13.73 | -26.28 |
| Net Income Including Noncontrolling Interests | - | 4.41 | -60.48 | -13.73 | -26.28 |
| Normalized Income | - | 0.17 | -60.48 | -5.28 | -26.34 |
| Diluted NI Availto Com Stockholders | - | 4.41 | -60.48 | -13.73 | -26.28 |
| Basic Average Shares | - | 2.40 | 3.31 | 2.93 | 3.32 |
| Diluted Average Shares | - | 2.40 | 3.31 | 2.93 | 3.32 |
| Reconciled Depreciation | - | 0.23 | 0.38 | 0.40 | 0.51 |
| Total Unusual Items | - | 5.36 | 0 | -8.45 | 0.06 |
| Total Unusual Items Excluding Goodwill | - | 5.36 | 0 | -8.45 | 0.06 |
| Special Income Charges | - | 0 | 0 | -7.50 | 0 |
| Write Off | - | 0 | 0.25 | - | - |
| Restructuring And Mergern Acquisition | - | - | 0 | 7.50 | 0 |
| Gain On Sale Of Security | - | 5.36 | 2.71 | -0.95 | 0.06 |
| General And Administrative Expense | - | 0.95 | 4.44 | 22.53 | 15.03 |
| Other Gand A | - | 0.95 | 3.34 | 7.05 | 4.15 |
| Salaries And Wages | - | 5.80 | 1.10 | 15.48 | 10.88 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Tevogen Bio Holdings Inc.this co. | TVGN | $41M | -1.57 | -2.42 | 154.2% | -1.89 |
| DocGo Inc. | DCGO | $56M | -0.31 | 0.39 | -126.7% | -0.47 |
| aTyr Pharma, Inc. | ATYR | $50M | -0.68 | 0.75 | -109.8% | -0.68 |
| Myomo, Inc. | MYO | $50M | -3.20 | 4.37 | -136.6% | -4.36 |
| Actuate Therapeutics, Inc. Common stock | ACTU | $46M |
| - |
| - |
| - |
| - |
| -2.09 |
| 5.86 |
| -280.5% |
| - |
| Accuray Incorporated | ARAY | $43M | -27.33 | 0.54 | -2.0% | 8.03 |
| Gossamer Bio, Inc. | GOSS | $42M | -0.24 | -0.34 | 138.8% | -1.31 |
| INmune Bio Inc. | INMB | $36M | -0.78 | 1.53 | -195.3% | -0.40 |
| Tvardi Therapeutics, Inc. | TVRD | $29M | -1.59 | 1.38 | -87.0% | -0.31 |
| Peer Median | - | -1.18 | 1.06 | -118.2% | -0.47 | |